Molecular radiotherapy using cleavable radioimmunoconjugates that target eGFR and γH2AX

Molecular Cancer Therapeutics

Volumn 12, Issue 11, 2013, Pages 2472-2482

  Cornelissen, Bart ^a   Waller, Andrew ^a   Able, Sarah ^a   Vallis, Katherine A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BENZYL PENTETIC ACID GAMMA HISTONE H2AX ANTIBODY NLS PEPTIDE SS EPIDERMAL GROWTH FACTOR INDIUM 111; BENZYL PENTETIC ACID RABBIT IMMUNOGLOBULIN G NLS PEPTIDE SS EPIDERMAL GROWTH FACTOR INDIUM 111; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; HISTONE GAMMA H2AX; HISTONE H2AX; INDIUM 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUGER ELECTRON SPECTROSCOPY; BINDING AFFINITY; BREAST CANCER; CANCER RADIOTHERAPY; CELL NUCLEUS; CELL SURVIVAL; CELLULAR DISTRIBUTION; CHROMATOPHORE; CLONOGENESIS; CONTROLLED STUDY; DISULFIDE BOND; DNA DAMAGE; DNA REPAIR; DRUG ABSORPTION; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG RETENTION; DRUG SPECIFICITY; DRUG UPTAKE; FEMALE; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IC 50; INTERNALIZATION; ISOTOPE LABELING; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION EXPOSURE; RADIOIMMUNOTHERAPY; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; X IRRADIATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; HISTONES; HUMANS; IMMUNOCONJUGATES; INDIUM RADIOISOTOPES; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887468746     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al.Gamma H2AX and cancer. Nat Rev Cancer 2008;8:957-67.
2. Ivashkevich A, Redon CE, Nakamura AJ, Martin RF, Martin OA. Use of the gamma-H2AX assay to monitor DNA damage and repair in translational cancer research. Cancer Lett 2012;327:123-33.
3. Cornelissen B, Kersemans V, Darbar S, Thompson J, Shah K, Sleeth K, et al. Imaging DNA damage in vivo using gammaH2AX-targeted immunoconjugates. Cancer Res 2011;71:4539-49.
4. Cornelissen B, Darbar S, Kersemans V, Allen PD, Falzone N, Barbeau J, et al. Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical. Nucl Med Biol 2012;39:1142-51.
5. Yasui LS. Molecular and cellular effects of Auger emitters: 2008-2011. Int J Radiat Biol 2012;88:864-70.
6. Reilly RM, Kiarash R, Cameron RG, Porlier N, Sandhu J, Hill RP, et al. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med 2000;41:429-38.
7. Reilly RM, Kiarash R, Sandhu J, Lee YW, Cameron RG, Hendler A, et al. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med 2000;41:903-11.
8. Saito G, Swanson JA, Lee KD. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv Drug Deliv Rev 2003;55:199-215.
9. du Manoir JM, Francia G,ManS, Mossoba M, Medin JA, Viloria-Petit A, et al. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006;12:904-16.
10. Cornelissen B, Kersemans V, McLarty K, Tran L, Reilly RM. 111Inlabeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1. Cancer Biother Radiopharm 2009;24:163-73.
11. Millar WT, Smith JF. Protein iodination using Iodogen. Int J Appl Radiat Isot 1983;34:639-41.
12. Cornelissen B, Hu M, McLarty K, Costantini D, Reilly RM. Cellular penetration and nuclear importation properties of 111In-labeled and 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells. Nucl Med Biol 2007;34:37-46.
13. Cai Z, Chen Z, Bailey KE, Scollard DA, Reilly RM, Vallis KA. Relationship between induction of phosphorylated H2AX and survival inbreast cancer cells exposed to 111In-DTPA-hEGF. J Nucl Med 2008;49:1353-61.
14. Kassis AI. The amazing world of auger electrons. Int J Radiat Biol 2004;80:789-803.
15. Cornelissen B, Vallis KA. Targeting the nucleus: an overview of Augerelectron radionuclide therapy. Curr Drug Discov Technol 2010;7: 263-79.
16. Adair JR, Howard PW, Hartley JA, Williams DG, Chester KA. Antibodydrug conjugates - a perfect synergy. Expert Opin Biol Ther 2012;12: 1191-1206.
17. Zolot RS, Basu S, Million RP. Antibody-drug conjugates. Nat Rev Drug Discov 2013;12:259-60.
18. Zhang W, Song J, Mu L, Zhang B, Liu L, Xing Y, et al. Improving anticancer activity and selectivity of camptothecin through conjugation with releasable substance P. Bioorg Med Chem Lett 2011;21: 1452-55.
19. Arunachalam B, Phan UT, Geuze HJ, Cresswell P. Enzymatic reduction of disulfide bonds in lysosomes: characterization of a gamma-interferon- inducible lysosomal thiol reductase (GILT). Proc Natl Acad Sci U S A 2000;97:745-50.
20. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 1988;263:17205-8.
21. Yang J, Chen H, Vlahov IR, Cheng JX, Low PS. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc Natl Acad Sci USA 2006;103:13872-77.
22. Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/ neu-amplified breast cancer. J Nucl Med 2007;48:1357-68.
23. Mishra A, Lai GH, Schmidt NW, Sun VZ, Rodriguez AR, Tong R, et al. Translocation of HIV TAT peptide and analogues induced by multiplexed membrane and cytoskeletal interactions. Proc Natl Acad Sci USA 2011;108:16883-88.
24. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009; 157:195-206.
25. Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, et al. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005;46:1898-1906.
26. Saker J, Kriegs M, Zenker M, Heldt JM, Eke I, Pietzsch HJ, et al. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks. J Nucl Med 2013;54:416-23.
27. Liu Z, Liu Y, Jia B, Zhao H, Jin X, Li F, et al. Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab. Mol Cancer Ther 2010;9:2297-308.
28. Pfost B, Seidl C, Autenrieth M, Saur D, Bruchertseifer F, Morgenstern A, et al. Intravesical alpha-radioimmunotherapy with 213Bi-anti- EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J Nucl Med 2009;50:1700-8.
29. Kassis AI, Adelstein SJ. Radiobiologic principles in radionuclide therapy. J Nucl Med 2005;46 Suppl 1:4S-12S.
30. Bender H, Takahashi H, Adachi K, Belser P, Liang SH, Prewett M, et al. Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res 1992;52:121-26.
31. Santoro L, Boutaleb S, Garambois V, Bascoul-Mollevi C, Boudousq V, Kotzki PO, et al. Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med 2009;50:2033-41.
32. Fasih A, Fonge H, Cai Z, Leyton JV, Tikhomirov I, Done SJ, et al. (1)(1)(1) In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer. Breast Cancer Res Treat 2012; 135:189-200.